SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA’s 2021 Product of the Year: Immune Support Award for its CV™ Defense product.
Focusing on true innovation, long-term market success and cutting-edge research, the NutraIngredients-USA Awards honor the best and brightest in ingredients, finished products, companies, people, and initiatives in the nutrition and dietary supplements industry.
CV™ Defense was created with a specific intent — to fortify daily immune health. The active ingredients in CV™ Defense are backed by hundreds of scientific studies for daily support of barrier immunity, innate immunity, and adaptive immunity. This powerful formula includes PEA, reishi mushroom extract, vitamins A and D, selenium and zinc.
“CV™ Defense by CV Sciences stood out in a crowded category,” said Stephen Daniells, PhD, Editor-in-Chief of NutraIngredients-USA. “Combining time-tested micronutrients with Levagen®+ PEA and an organic reishi mushroom extract with concentrated β-glucan, the formulation offers consumers something familiar and yet different. PEA is supported by interesting science, and the product already boasts strong initial sales in the marketplace.”
“We are honored to be recognized for our innovation in a category that has been top of mind for consumers all year: immune health,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “Such recognition would not have been possible without the hard work and dedication of our expert staff, scientists, and advisors – who are the heart of who we are as a wellness company. This award also validates our strategic decision to expand our product portfolio beyond the hemp-derived CBD category that we pioneered. There is much more to come as we continue to diversify our offerings to meet consumer demand for innovative wellness products backed by nature and science.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing, and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 7,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
About the NutraIngredients-USA Awards
Focusing on true innovation, long-term market success and cutting-edge research, the NutraIngredients-USA Awards honor the best and brightest in ingredients, finished products, companies, people, and initiatives in the nutrition and dietary supplements industry. For more information, please visit: www.NutraIngredientsUSA-Awards.com The NutraIngredients-USA Awards are organized by NutraIngredients-USA.com, the key news source for the functional food & beverage and dietary supplement industries. Covering scientific, regulatory and industry issues, the website offers a reference for all stakeholders in supplements and nutrition. Thanks to its blend of text, video and podcast content, the news can not only be read but also heard directly from the lips of the people making the headlines.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/335e4222-0fa3-42c7-9efb-7618df391fd0
Media Contact
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
Investor Contact
ICR
Reed Anderson
646-277-1260
CVSciences@icrinc.com
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…